Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics. Under the agreement, Catalent will conduct formulation development and clinical manufacturing activities for Silexion's next-generation siRNA candidate, SIL204, at its state-of-the-art facility in Limoges, France. The collaboration will focus on optimizing both the systemic

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with intratumoral administration to focus on primary tumors, offering a comprehensive approach to treating KRAS-driven pancreatic cancer. The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that systemic adminis

Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company's management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. The newly completed strategic plan builds upon Silexion's recent promising preclinical data and is designed to maximize SIL-204'

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. Ilan Hadar, Chairman and CEO of Silexion, commented: "2024 was a transformative year for Silexion, marked by our Nasdaq listing and the advancement of our clinical and preclinical pipeline. Over the past year, we made important progress, culminating in significant milestones especially for our second-generation candi

Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative Therapy; Wall Street Maintains Buy Rating and $9 Price Target representing a signifcant premium of almost +600% over current prices; Silexion's new expanded development plan expected to be completed shortly; Precision Oncology M&A Market has heated up in recent years with a series of Multi-Billion Dollar Acquisitions in the field PESG Research releases a report covering Silexion Therapeutics' (NASDAQ:SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SI

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread. These findings represent a significant advancement over previously reported data by providing further validation of SIL204's efficacy in the more clinically relevant orthotopic setting, where human pancreatic tumor cells are implanted directly into the pan

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could validate systemic efficacy against metastatic disease for the first time. Reportedly, Maxim Group maintains a $9 price target and strong buy rating, citing the company's growing clinical trajectory and RNAi platform validation. With a data readout expected this month, this could be a major catalyst for the company, as interest for innovative KRAS-targeting therapies continues to rise PESG Research releases a new market update on Silexion Therapeutics (NASDAQ:SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in o

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models. The study specifically evaluated two critical aspects of SIL-204's potential therapeutic profile: SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic p

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warr

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price Target as Company Advances RNAi Platform for KRAS-Driven Cancers Amid Hot Precision Oncology M&A Market and a series of Multi-Billion Dollar Acquisitions in the field PESG Research releases new market update: Silexion Therapeutics (NASDAQ:SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing

3 - Silexion Therapeutics Corp (0002022416) (Issuer)

424B3 - Silexion Therapeutics Corp (0002022416) (Filer)

EFFECT - Silexion Therapeutics Corp (0002022416) (Filer)

POS AM - Silexion Therapeutics Corp (0002022416) (Filer)

AW - Silexion Therapeutics Corp (0002022416) (Filer)

AW - Silexion Therapeutics Corp (0002022416) (Filer)

424B3 - Silexion Therapeutics Corp (0002022416) (Filer)

EFFECT - Silexion Therapeutics Corp (0002022416) (Filer)

POS AM - Silexion Therapeutics Corp (0002022416) (Filer)

8-K - Silexion Therapeutics Corp (0002022416) (Filer)

POS AM - Silexion Therapeutics Corp (0002022416) (Filer)

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of

Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)